Phaseline

Companies › AvenCell Europe

AvenCell Europe: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allo-RevCAR01-T-CD123
Allogeneic multi-edited CAR-T cells with reversed CAR (RevCAR) bridged to CD123 via R-TM12
CD123Phase 1Acute Myeloid Leukemia, in RelapseMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05949125Allo-RevCAR01-T-CD123Phase 1Acute Myeloid Leukemia, in RelapseOncologyMay 2027

Targets

CD123 (1)

Companies with the same targets

Chongqing Precision Biotech Cellectis Gilead Sciences MacroGenics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.